Scientific publisher Nature Publishing Group (NPG) and the American Society of Gene & Cell Therapy (ASGCT) have announced a new online open access journal, Molecular Therapy – Oncolytics.
Molecular Therapy - Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer. The journal is a sister journal to the well-established and highly respected journal, Molecular Therapy. Molecular Therapy - Oncolytics builds upon the success of Molecular Therapy, Molecular Therapy – Nucleic Acids, and Molecular Therapy - Methods & Clinical Development.
It will provide a unique forum for work in the burgeoning fields of oncolytic virotherapy and T cell-based therapies, considering top-quality, cutting edge research that employs innovative molecular and cellular approaches that target cancer cells for destruction, whether by viruses, other microorganisms, vaccination, or by transfer of cells and/or genes.
Molecular Therapy – Oncolytics will make all content freely available to all researchers worldwide. Authors of accepted manuscripts are charged an article-processing fee dependent upon article type and license chosen. Articles are published under a choice of Creative Commons licenses.
The editorial team is led by Dr. Yuman Fong, Chair of the Department of Surgery at City of Hope. Molecular Therapy – Oncolytics joins over 60 journals in NPG's journal portfolio that have either an open access option or are entirely open access.
